Looking Ahead With SCLC: ADCs and Other Novel Agents

Author(s):

Benjamin P. Levy, MD,Misty D. Shields, MD, PhD

Panelists discuss how emerging antibody-drug conjugate (ADC) data from TROPiCS-03 and IDeate-Lung01 suggest potential in extensive-stage small cell lung cancer (ES-SCLC), impacting sequencing with current therapies. T-cell engagers like BI 764532 and HPN328 may reshape treatment. MRI surveillance, per retrospective data and MAVERICK, offers an alternative to prophylactic cranial irradiation (PCI), though select factors may still justify PCI use.

EP: 1.An Expert Insights on Recent Advancements in LS-SCLC

EP: 2.The Key Updates in the Treatment of ES-SCLC

EP: 3.An Expert Perspectives on Tarlatamab in ES-SCLC

Now Viewing

EP: 4.Looking Ahead With SCLC: ADCs and Other Novel Agents

EP: 5.The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP: 7.The New Targeted Approaches in Unresectable Early-Stage NSCL

EP: 8.Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

Video content above is prompted by the following:

What is your perspective on the emerging data for ADCs in this space? Where might these fit into the evolving treatment paradigm, and how would you sequence them with other available therapies?
TROPiCS-03 (Saci): Dowlati A, et al. WCLC 2024. Abs OA04.04
I-DXd (IDeate-Lung01): Rudin CM, et al. WCLC 2024. Abs OA04
What are your thoughts on current strategies and emerging data surrounding T-cell engagers, and how might they impact the treatment landscape?
BI 764532 (DAREON-8): Peters S, et al. ASCO 2024. Abs TPS8127
HPN328: Choudhury N, et al. ESMO 2023. Abs 698P
What evidence supports MRI surveillance as an alternative to PCI for brain metastasis management in ES-SCLC? What factors might still warrant PCI?
Retrospective data: Chen Y, et al. Respir Res. 2022;23:274.
MAVERICK trial: NCT04155034